OxiGene Inc (OXGN)

0.71
0.06 9.23
NASDAQ : Health Care
Prev Close 0.65
Open 0.67
Day Low/High 0.67 / 0.72
52 Wk Low/High 0.49 / 1.40
Volume 135.33K
Avg Volume 534.20K
Exchange NASDAQ
Shares Outstanding 26.54M
Market Cap 18.58M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
OxiGene (OXGN) Highlighted As Today's Perilous Reversal Stock

OxiGene (OXGN) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified OxiGene (OXGN) as a "perilous reversal" (up big yesterday but down big today) candidate

Small-Cap Biotech on the Verge of a Breakout: ABIO

Small-Cap Biotech on the Verge of a Breakout: ABIO

Here's how to trade Arca Biopharma.

OxiGene (OXGN) Moving On Heavy Pre-Market Trading

OxiGene (OXGN) Moving On Heavy Pre-Market Trading

Trade-Ideas LLC identified OxiGene (OXGN) as a pre-market mover with heavy volume candidate

Oxigene Surprises With Positive Ovarian Cancer Study Success

Oxigene Surprises With Positive Ovarian Cancer Study Success

A combination of Oxigene's Zybrestat and Roche's Avastin delayed the regrowth of tumors in women with advanced ovarian cancer.

UPDATE -- OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I Of ZYBRESTAT(R) In Combination With Avastin(R) For Recurrent Ovarian Cancer

UPDATE -- OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I Of ZYBRESTAT(R) In Combination With Avastin(R) For Recurrent Ovarian Cancer

Trial Achieves Primary Efficacy Endpoint of a Statistically Significant Increase in Progression-Free Survival

OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I Of ZYBRESTAT(R) In Combination With Avastin(R) For Recurrent Ovarian Cancer

OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I Of ZYBRESTAT(R) In Combination With Avastin(R) For Recurrent Ovarian Cancer

Trial Achieves Primary Efficacy Endpoint of a Statistically Significant Reduction in Progression-Free Survival

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

OXiGENE To Present Phase I Data Demonstrating Antitumor Activity Of OXi4503 In Patients With Acute Myeloid Leukemia And Myelodysplastic Syndromes

OXiGENE To Present Phase I Data Demonstrating Antitumor Activity Of OXi4503 In Patients With Acute Myeloid Leukemia And Myelodysplastic Syndromes

Poster Presentation on December 7, 2013 at the ASH Conference in New Orleans

OXiGENE To Present Preclinical Data Demonstrating Antitumor Activity Of ZYBRESTAT(R) In Pancreatic Neuroendocrine Tumor Model

OXiGENE To Present Preclinical Data Demonstrating Antitumor Activity Of ZYBRESTAT(R) In Pancreatic Neuroendocrine Tumor Model

Poster Presentation Slated for October 20, 2013 at AACR-NCI-EORTC Conference in Boston

4 Stocks Under $10 in Breakout Territory

4 Stocks Under $10 in Breakout Territory

These stocks are within range of triggering breakout trades.

4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Faruqi & Faruqi, LLP Launches An Investigation Against OXiGENE, Inc. (OXGN) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors

Faruqi & Faruqi, LLP Launches An Investigation Against OXiGENE, Inc. (OXGN) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of OXiGENE, Inc.